Cargando…

Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial

IMPORTANCE: The prevalence of atrial fibrillation (AF) increases with age and is more common in frail patients. However, data are lacking on outcomes of oral anticoagulants (OACs) in very elderly patients with AF with frailty, who are ineligible for standard anticoagulant treatment. OBJECTIVE: To co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akashi, Shintaro, Oguri, Mitsutoshi, Ikeno, Eiichiro, Manita, Mamoru, Taura, Junki, Watanabe, Saori, Hayashi, Takuya, Akao, Masaharu, Okumura, Ken, Akishita, Masahiro, Yamashita, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399878/ https://www.ncbi.nlm.nih.gov/pubmed/35997978 http://dx.doi.org/10.1001/jamanetworkopen.2022.28500

Ejemplares similares

Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial
por: Yoshida, Tetsuro, et al.
Publicado: (2022)

Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE–AF Randomized Clinical Trial
por: Kuroda, Masaru, et al.
Publicado: (2022)

Laboratory Test Predictors for Major Bleeding in Elderly (≥80 Years) Patients With Nonvalvular Atrial Fibrillation Treated With Edoxaban 15 mg: Sub‐Analysis of the ELDERCARE‐AF Trial
por: Mikami, Takeshi, et al.
Publicado: (2022)

A multicenter prospective cohort study to investigate the effectiveness and safety of apixaban in Japanese elderly atrial fibrillation patients (J‐ELD AF Registry)
por: Okumura, Ken, et al.
Publicado: (2019)

Clinical Outcomes of Very Elderly Patients With Atrial Fibrillation Receiving On‐label Doses of Apixaban: J‐ELD AF Registry Subanalysis
por: Okada, Masato, et al.
Publicado: (2021)

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)
por: De Caterina, Raffaele, et al.
Publicado: (2019)

The Eldercare Consultant
por: Feola, Becky
Publicado: (2015)

Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial
por: Kato, Eri Toda, et al.
Publicado: (2016)

Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT‐AF/VTE)—Trial design
por: Colonna, Paolo, et al.
Publicado: (2018)

Impact of anemia on the clinical outcomes in elderly patients with atrial fibrillation receiving apixaban: J-ELD AF registry subanalysis
por: Tanaka, Nobuaki, et al.
Publicado: (2022)

Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF Program
por: Chao, Tze-Fan, et al.
Publicado: (2023)

Edoxaban use in the context of dental procedures: analysis from the EMIT-AF/VTE database
por: Chen, Cathy, et al.
Publicado: (2023)

Editorial to the Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF Japan): One‐year safety and effectiveness analyses
por: Nagashima, Koichi, et al.
Publicado: (2020)

Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): One‐year safety and effectiveness analyses
por: Yamashita, Takeshi, et al.
Publicado: (2020)

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
por: Hohnloser, Stefan H, et al.
Publicado: (2019)

Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): Three‐month interim analysis results
por: Yamashita, Takeshi, et al.
Publicado: (2018)

The development of smart eldercare in China
por: Chen, Honglin, et al.
Publicado: (2022)

Corrigendum to: Edoxaban in AF patients with PCI by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial
Publicado: (2020)

Corrigendum to: Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
Publicado: (2019)

Edoxaban in patients with non-valvular atrial fibrillation after percutaneous coronary intervention: ENCOURAGE-AF design
por: Baldus, Stephan, et al.
Publicado: (2023)

Predictive Factors and Clinical Events Associated with Edoxaban Interruption and Heparin Bridging Strategy: EMIT-AF/VTE
por: Santamaria, Amparo, et al.
Publicado: (2023)

The Influence of Nursing Home, Ward, and Eldercare Workers on the Number of Resident Handlings Performed per Shift in Eldercare
por: Kyriakidis, Stavros, et al.
Publicado: (2021)

Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial
por: Kozieł, Monika, et al.
Publicado: (2020)

Safety and effectiveness of edoxaban in Japanese patients with nonvalvular atrial fibrillation: Final report of a two‐year postmarketing surveillance study (ETNA‐AF‐Japan)
por: Yamashita, Takeshi, et al.
Publicado: (2021)

Remote Arrhythmia Detection for Eldercare in Malaysia
por: Chew, Kevin Thomas, et al.
Publicado: (2021)

Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial
por: Fanola, Christina L., et al.
Publicado: (2018)

Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study
por: de Vries, T. A. C., et al.
Publicado: (2021)

Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial
por: Hohnloser, Stefan H, et al.
Publicado: (2020)

Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry
por: Boriani, Giuseppe, et al.
Publicado: (2021)

Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program
por: De Caterina, Raffaele, et al.
Publicado: (2021)

Spanish and Swedish eldercare managers’ influence on employees
por: Nordin, Maria, et al.
Publicado: (2018)

The Different Models of Community Eldercare Service in China
por: Zhang, Lei, et al.
Publicado: (2019)

Unveiling the Evolution of Eldercare Facilities in Rural China: Tracing the Trajectory from Eldercare Support Pattern and Service to Facilities for the Aging Population
por: Zhang, Ziqi, et al.
Publicado: (2023)

Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study
por: Goette, Andreas, et al.
Publicado: (2018)

The Role of Sleep Disturbance, Depression and Anxiety in Frail Patients with AF–Gender Differences
por: Jankowska-Polańska, Beata, et al.
Publicado: (2020)

Age-dependent risk for thromboembolism in atrial fibrillation: The Fushimi AF registry
por: Esato, Masahiro, et al.
Publicado: (2022)

Baseline characteristics of edoxaban treatment in routine clinical practice for patients with non-valvular atrial fibrillation in China (ETNA-AF-China)
por: Guo, X Y, et al.
Publicado: (2023)

Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry
por: Patti, Giuseppe, et al.
Publicado: (2022)

Predictors for Stroke and Death in Non-Anticoagulated Asian Patients with Atrial Fibrillation: The Fushimi AF Registry
por: Hamatani, Yasuhiro, et al.
Publicado: (2015)

Out of the ordinary: Media reports on wet eldercare facilities
por: Jönson, Håkan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2mae2i34uef883h46vuc1hj3qm